About OPKO Health, Inc. 
OPKO Health, Inc.
Pharmaceuticals & Biotechnology
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.
Company Coordinates 
Company Details
4400 Biscayne Blvd , MIAMI FL : 33137
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 41 Schemes (11.07%)
Foreign Institutions
Held by 101 Foreign Institutions (4.25%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Dr. Phillip Frost
Chairman of the Board, Chief Executive Officer
Dr. Jane Hsiao
Vice Chairman of the Board, Chief Technical Officer
Dr. Jon Cohen
Director, Executive Chairman of BioReference Laboratories
Mr. Steven Rubin
Executive Vice President - Administration, Director
Dr. Robert Fishel
Independent Director
Dr. Anthony Japour
Independent Director
Dr. Richard Krasno
Independent Director
Dr. Richard Lerner
Independent Director
Dr. Roger Medel
Independent Director
Revenue and Profits:
Net Sales:
157 Million
(Quarterly Results - Jun 2025)
Net Profit:
-148 Million
Pharmaceuticals & Biotechnology
USD 1,169 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.06
-14.14%
0.90






